Background
The urokinase plasminogen activation (uPA) system, including the ligand uPA, the urokinase plasminogen activation receptor (uPAR), and the plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2), is a serine proteinase system involved in the degradation of extracellular matrix (ECM). The uPA system plays an important role in tumor invasion and metastasis, and is associated with poor prognosis of cancers. [1] [2] [3] [4] The uPA ligand binds to the uPAR receptor, a three-domain glycolipid-anchored cell surface protein. The binding of inactive precursor pro-uPA to uPAR-activated surface-bound plasminogen results in the formation of plasmin and matrix metalloproteinase, which enhances the degradation of most components of ECM and the basement membranes. [5] [6] [7] It has been reported that the levels of uPA components were associated with poor prognosis and high mortality of a wide range of malignancies 1, 2, [8] [9] [10] due to their roles in metastasis. The effects of uPA/uPAR on plasminogen activation are regulated by their specific inhibitors PAI-1 and PAI-2.
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Epidemiological studies have evidenced that both environmental carcinogens and genetic factors contributed to cancer susceptibility. Given that single-nucleotide polymorphisms (SNPs) within the promoter or other regulatory regions of the genes encoding the uPA system may affect their expression and activities, SNP identification based on genotyping approaches is useful for investigating the association between these SNPs, cancer risk, and prognosis. 14 In the past few decades, a large number of epidemiological studies have evaluated the association between the genetic variations of genes encoding the uPA system and the risk of breast cancer, prostate cancer, non-small-cell lung cancer, gastric cancer, endometrial cancer, hepatocellular carcinoma, and oral cancer; however, the results of these studies were conflicting. [14] [15] [16] [17] [18] [19] [20] Interestingly, a meta-analysis has found an association between the PAI-1 4G/5G polymorphism (rs1799768) and increased cancer risk. 21 In the present study, we conducted a meta-analysis to systemically evaluate the association between the uPA system polymorphisms and cancer risk.
Methods
selection of published studies
Published studies, which have been published no later than November 13, 2014, were identified by searching the PubMed, Embase, and Web of Science databases using the following MeSH terms and keywords: uPA (PLAU), uPAR, urokinase plasminogen activation, urokinase plasminogen activation receptor, polymorphism, cancer, carcinoma, and neoplasms. The reference lists of retrieved studies were also searched to identify relative studies. Studies included in the present meta-analysis were as follows: 1) articles investigating the association between the uPA system polymorphisms rs4065, rs2227564, and rs344781 and cancer risk; 2) casecontrol studies; 3) studies providing genotype frequency for computing odds ratios (ORs) with 95% confidence intervals (CIs); and 4) studies with full text articles. The exclusion criteria were as follows: 1) only case population studies without comparison outcomes reported or not possible to determine comparison outcomes; 2) duplicated publications; and 3) benign tumors and/or precancerous lesions.
Data extraction
Two investigators independently screened the manuscript titles, abstracts, and full texts using a standardized extraction form. For conflicting evaluation, an agreement was reached based on consensus and discussion. For each study, the following data were extracted: the first author's name, year of publication, country of origin, ethnicity, genotyping methods, source of control, cancer type, total numbers of cases and controls, and genotype distributions in cases and controls. We did not define a minimum number of patients in each study for the present meta-analysis.
evaluation of study quality and validation of study
The quality of studies was assessed by quality scores using a standardized extraction form according to previous studies with minor modification (Table S1) . 22, 23 The total quality score ranged from 0 (the lowest quality) to 20 (the highest quality). The analyses were stratified according to the study quality.
statistical analyses
Statistical analyses were performed using STATA software (Version 11.0; StataCorp LP, College Station, TX, USA), and all tests were two-sided with a significant level of 0.05, unless stated otherwise. The Hardy-Weinberg equilibrium (HWE) in controls was assessed using chi-squared test, and a P-value 0.05 was considered as significant disequilibrium. If the HWE existed (P0.05) or it was impossible to evaluate the HWE, sensitivity analysis was performed. The strength of the association between the uPA system polymorphisms and cancer risk was evaluated on the basis of ORs with 95% CIs. The Q-statistic was used to test heterogeneities among the studies included in the meta-analysis. 24 When the Q-test P-value was not 0.1, fixed effect model with MantelHaenszel method was used to calculate the pooled ORs. 25 Otherwise, a random effect model with inverse variance method was used. Taking the uPA polymorphism rs4065 as an example, pooled ORs were obtained from the combination of all studies by heterozygote comparison (TC vs CC), homozygote comparison (TT vs CC), dominant and recessive models (TT + TC vs CC and TT vs TC + CC), and allelic comparison (T vs C). Similarly, comparison of the results of other polymorphisms was also obtained. In addition, we also performed stratification analyses according to ethnicity and quality score: high-quality studies (quality score 15) vs low-quality studies (quality score 15). Begg's and Egger's tests were used to evaluate publication bias. 26, 27 Results characteristics of the studies A total of 62 studies were included in this meta-analysis based on the search strategy using different combinations of keywords ( Figure 1 
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uPa system and cancer risk full texts, 20 case-control studies from 13 articles met our inclusion criteria. 14, [17] [18] [19] [20] [28] [29] [30] [31] [32] [33] [34] [35] A total of 7,037 cancer cases and 10,094 controls were included in the 20 case-control studies. The characteristics of these studies are listed in Table 1 . Among them, seven studies including 1,233 cancer cases and 1,919 controls investigated the uPA polymorphism rs4065, six studies including 2,343 cancer cases and 2,780 controls studied the uPA polymorphism rs2227564, and seven studies including 2,265 cancer cases and 3,241 controls were about the uPAR polymorphism rs344781. The distribution of genotypes in the controls of all studies was consistent with HWE.
Meta-analysis
The significance of the association between uPA and uPAR polymorphisms and cancer risk is shown in Table 2 . Overall, no significant association was found between the uPA polymorphism rs2227564 and cancer risk based on all genetic models (Table 2) , whereas significantly increased cancer risk was associated with the uPA polymorphism rs4065 were associated with increased cancer risk in hospital-based control studies, which was consistent with the results from studies of high quality. No significant association between the uPAR polymorphism rs344781and cancer risk was detected in the studies from population-based control. Abbreviations: CI, confidence interval; HB, hospital-based case-control; Ht, heterozygote; N, numbers of involved studies; Non, nondigestive system cancer studies; OR, odds ratio; PB, population-based case-control study; uPA, urokinase plasminogen activation; uPar, urokinase plasminogen activation receptor; Vr, variant; Vr ho, variant homozygote; WT, wild-type; WT ho, wide-type homozygote; Y, digestive system cancer studies.
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Discussion
The uPA system plays an essential role in the degradation and regeneration of basement membrane and ECM, as well as cancer metastasis. 11, 12 The biological function of the uPA system may be impaired by SNPs within genes encoding the uPA system, resulting in altered susceptibility to cancers. The effects of genetic variations of the uPA system in cancer development have been recognized in recent years; however, the results are contradictory. 14, [17] [18] [19] [20] In the present study, we provided a comprehensive meta-analysis to evaluate the association of the uPA system polymorphisms and cancer risk. To the best of our knowledge, this is the first systematic meta-analysis addressing the association between the uPA system polymorphisms (not the PAI-1) and cancer risk.
Yoshimoto et al 37 reported that the CC genotype exhibited the strongest uPA affinity for substrates and inhibitors, resulting in the formation of uPA/uPAR and uPA/PAI-1 complexes and the activation of the uPA system. Our meta-analysis suggests that the T allele in the uPA polymorphism rs4065 was associated with a high incidence of cancers. Therefore, we speculate that the activation of the uPA system may be interrupted by the lower affinity of the rs4065 variant with its substrates and inhibitors. Based on stratified analysis of ethnicity, significant association between uPA polymorphism rs4065 and cancer risk was found in Asians. However, lack of case-control studies limited our evaluation on the association between the uPA polymorphism rs4065 and cancer risk among other ethnicities. In the subgroup analysis of cancer types, a significant association was identified between the polymorphism rs4065 and increased risk of both digestive and nondigestive system cancers based on a dominant model, which was consistent with the results from high-quality studies.
Regarding the general analysis of the uPAR polymorphism, we showed that the presence of minor alleles significantly increased the risk of cancers than major alleles, suggesting that genetic variations significantly modify the host susceptibility to cancers. In the subgroup analysis of ethnicity, significant association was identified between the polymorphism rs344781 and increased cancer risk in Asians rather than Caucasians. The inconsistent results between these two ethnicities may be explained by distinct lifestyles and environmental factors of these two ethnic groups. In the subgroup analysis of cancer types, we detected an association between the polymorphism rs344781 and the risk of nondigestive system cancers, but not the digestive system cancers. This difference between digestive and nondigestive system cancers may be explained by the differential expression, function, and regulatory mechanisms of the uPA and uPAR systems in various tissues and tumors. [38] [39] [40] [41] [42] General analysis of the uPA polymorphism rs2227564 showed no significant association between the uPA polymorphism rs2227564 and cancer risk. However, casecontrol studies of large scale are necessary to ascertain the accurate effects of the rs2227564 polymorphism on cancer development.
A number of limitations in the present meta-analysis should be addressed. First, lack of original data of the reviewed studies limited our evaluation of the potential effects of gene-gene and gene-environment interactions. Second, all case-control studies were from People's Republic of China, Taiwan, Europe, the US, and India. These results may be applicable only to the relative ethnicities. Third, the meta-analysis study should provide a more accurate evaluation on the association between the uPA polymorphisms and cancer risk by considering classic cancer risk factors, submit your manuscript | www.dovepress.com
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In summary, the present meta-analysis study suggests that the uPA polymorphism rs4065 and the uPAR polymorphism rs344781 were associated with increased cancer risk in Asian population. In addition, subgroup analysis of cancer types suggests that the uPAR polymorphism rs344781 was associated with increased risk of nondigestive system cancers, but not the digestive system cancers. However, it is important to include larger samples with detailed clinical data, standardized unbiased genotyping methods, homogeneous cancer patients, and well-matched controls to further understand the association between the uPA polymorphisms and cancer risk in the future.
Conclusion
This meta-analysis found that the uPA polymorphism rs4065 and the uPAR polymorphism rs344781, not the uPA polymorphism rs2227564, are associated with increased cancer risk. However, well-designed case-control studies with larger sample size and more ethnicities are necessary to validate our findings in the future.
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